Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet aggregation and aspirin response in type 1 diabetes
2019-004772-19Phase 4Active
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of aspirin in diabetes mellitus type 1 (T1D), cardiac morbidity and diabetic glomerulosclerosis (3 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Platelet aggregation without/off aspirin in T1D vs healthy controls. Started Jan 2020; status: active.
02
Drugs
aspirin
03
Conditions
diabetes mellitus type 1 (T1D)cardiac morbiditydiabetic glomerulosclerosis
Beyond the preview
Go deeper on 2019-004772-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004772-19.